Targeting targeted therapy.

The emergence of effective cancer chemotherapy is one of the major medical advances of the second half of the 20th century. In certain neoplasms — such as gestational choriocarcinoma, childhood acute lymphoblastic leukemia, and subgroups of Hodgkin's disease and non-Hodgkin's lymphoma — chemotherapy is often curative, and the promise of long-term survival makes therapy well worth the risk of adverse effects and the financial costs. Moreover, adjuvant chemotherapy for breast, colon, or lung cancer can augment the survival benefit afforded by surgical management. Even in patients with advanced solid tumors or recurrences despite surgery, chemotherapy can offer lengthened survival of . . .

[1]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Harris,et al.  Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  S. Barsky,et al.  The multifocality of bronchioloalveolar lung carcinoma: evidence and implications of a multiclonal origin. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[7]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[8]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[9]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.